Loading…
The long‐standing history of Corynebacterium parvum, immunity, and viruses
We report a review of all the experimental and clinical studies performed in the last 60 years on the antiviral activity of inactivated Corynebacterium parvum (Cutibacterium acnes). This bacterium has been originally investigated and used for its oncolytic properties linked to immunomodulating activ...
Saved in:
| Published in: | Journal of medical virology 2020-11, Vol.92 (11), p.2429-2439 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3580-8e705151389c0d23eba58976a5e95348e6caac1347576cb4a2caa4d0ff8c640d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3580-8e705151389c0d23eba58976a5e95348e6caac1347576cb4a2caa4d0ff8c640d3 |
| container_end_page | 2439 |
| container_issue | 11 |
| container_start_page | 2429 |
| container_title | Journal of medical virology |
| container_volume | 92 |
| creator | Palmieri, Beniamino Vadalà, Maria Roncati, Luca Garelli, Andrea Scandone, Francesco Bondi, Moreno Cermelli, Claudio |
| description | We report a review of all the experimental and clinical studies performed in the last 60 years on the antiviral activity of inactivated Corynebacterium parvum (Cutibacterium acnes). This bacterium has been originally investigated and used for its oncolytic properties linked to immunomodulating activity, but the interest to successfully prevent and treat bacterial, fungal, and viral infections and lethality, uprising the innate immunity barriers produced many experimental models and very few clinical studies. The dramatic defenseless situation due to impending CoViD‐19 pandemic claims to exhume and highlight this aspecific strategy in preventive and therapeutic settings; as a matter of fact, no new or mutated virus can potentially escape to this strong innate immune surveillance strengthened by adequate C. parvum protocols. |
| doi_str_mv | 10.1002/jmv.26100 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7300755</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2408192211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3580-8e705151389c0d23eba58976a5e95348e6caac1347576cb4a2caa4d0ff8c640d3</originalsourceid><addsrcrecordid>eNp1kctqGzEUhkVpaJy0i75AGeimgUxypNFtNoFicsWlm7RbIWs0tsyM5EozLt71EfKMeZKodRqSQlfnCH36ODo_Qu8xnGAAcrrqNyeE5_YVmmCoeVmDwK_RBDDlJeeY7aODlFYAIGtC3qD9ilBBBPAJmt0ubdEFv7j_dZcG7RvnF8XSpSHEbRHaYpqrt3NtBhvd2BdrHTdjf1y4vh-9G7bHRX5TbFwck01v0V6ru2TfPdZD9O3i_HZ6Vc6-Xl5PP89KUzEJpbQCGGa4krWBhlRZz2QtuGa2ZhWVlhutDa6oYIKbOdUkn2kDbSsNp9BUh-hs512P8942xvoh6k6to-t13KqgnXp5491SLcJGiQpAMJYFnx4FMfwYbRpU75KxXae9DWNShILEeVUYZ_TjP-gqjNHn72WK8lpyxnimjnaUiSGlaNunYTCo3xmpnJH6k1FmPzyf_on8G0oGTnfAT9fZ7f9N6ubL953yAZJtnMc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2446986556</pqid></control><display><type>article</type><title>The long‐standing history of Corynebacterium parvum, immunity, and viruses</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Palmieri, Beniamino ; Vadalà, Maria ; Roncati, Luca ; Garelli, Andrea ; Scandone, Francesco ; Bondi, Moreno ; Cermelli, Claudio</creator><creatorcontrib>Palmieri, Beniamino ; Vadalà, Maria ; Roncati, Luca ; Garelli, Andrea ; Scandone, Francesco ; Bondi, Moreno ; Cermelli, Claudio</creatorcontrib><description>We report a review of all the experimental and clinical studies performed in the last 60 years on the antiviral activity of inactivated Corynebacterium parvum (Cutibacterium acnes). This bacterium has been originally investigated and used for its oncolytic properties linked to immunomodulating activity, but the interest to successfully prevent and treat bacterial, fungal, and viral infections and lethality, uprising the innate immunity barriers produced many experimental models and very few clinical studies. The dramatic defenseless situation due to impending CoViD‐19 pandemic claims to exhume and highlight this aspecific strategy in preventive and therapeutic settings; as a matter of fact, no new or mutated virus can potentially escape to this strong innate immune surveillance strengthened by adequate C. parvum protocols.</description><identifier>ISSN: 0146-6615</identifier><identifier>EISSN: 1096-9071</identifier><identifier>DOI: 10.1002/jmv.26100</identifier><identifier>PMID: 32472706</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Animals ; Antiviral activity ; C. parvum ; Clinical Trials as Topic ; coronavirus ; Corynebacterium ; COVID-19 ; COVID-19 - prevention & control ; Humans ; immune responses ; Immunity ; Immunity, Innate ; Immunologic Factors - administration & dosage ; Immunologic Factors - therapeutic use ; Immunologic Surveillance ; immunomodulation ; Immunosurveillance ; Innate immunity ; Lethality ; Oncolysis ; Pandemics ; Propionibacterium acnes - immunology ; Review ; Reviews ; Virology ; Virus Diseases - immunology ; Virus Diseases - prevention & control ; Virus Diseases - therapy ; Viruses</subject><ispartof>Journal of medical virology, 2020-11, Vol.92 (11), p.2429-2439</ispartof><rights>2020 Wiley Periodicals LLC</rights><rights>2020 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3580-8e705151389c0d23eba58976a5e95348e6caac1347576cb4a2caa4d0ff8c640d3</citedby><cites>FETCH-LOGICAL-c3580-8e705151389c0d23eba58976a5e95348e6caac1347576cb4a2caa4d0ff8c640d3</cites><orcidid>0000-0001-7873-5072 ; 0000-0003-3396-0000 ; 0000-0002-0871-138X ; 0000-0002-6652-9148</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32472706$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Palmieri, Beniamino</creatorcontrib><creatorcontrib>Vadalà, Maria</creatorcontrib><creatorcontrib>Roncati, Luca</creatorcontrib><creatorcontrib>Garelli, Andrea</creatorcontrib><creatorcontrib>Scandone, Francesco</creatorcontrib><creatorcontrib>Bondi, Moreno</creatorcontrib><creatorcontrib>Cermelli, Claudio</creatorcontrib><title>The long‐standing history of Corynebacterium parvum, immunity, and viruses</title><title>Journal of medical virology</title><addtitle>J Med Virol</addtitle><description>We report a review of all the experimental and clinical studies performed in the last 60 years on the antiviral activity of inactivated Corynebacterium parvum (Cutibacterium acnes). This bacterium has been originally investigated and used for its oncolytic properties linked to immunomodulating activity, but the interest to successfully prevent and treat bacterial, fungal, and viral infections and lethality, uprising the innate immunity barriers produced many experimental models and very few clinical studies. The dramatic defenseless situation due to impending CoViD‐19 pandemic claims to exhume and highlight this aspecific strategy in preventive and therapeutic settings; as a matter of fact, no new or mutated virus can potentially escape to this strong innate immune surveillance strengthened by adequate C. parvum protocols.</description><subject>Animals</subject><subject>Antiviral activity</subject><subject>C. parvum</subject><subject>Clinical Trials as Topic</subject><subject>coronavirus</subject><subject>Corynebacterium</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>Humans</subject><subject>immune responses</subject><subject>Immunity</subject><subject>Immunity, Innate</subject><subject>Immunologic Factors - administration & dosage</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunologic Surveillance</subject><subject>immunomodulation</subject><subject>Immunosurveillance</subject><subject>Innate immunity</subject><subject>Lethality</subject><subject>Oncolysis</subject><subject>Pandemics</subject><subject>Propionibacterium acnes - immunology</subject><subject>Review</subject><subject>Reviews</subject><subject>Virology</subject><subject>Virus Diseases - immunology</subject><subject>Virus Diseases - prevention & control</subject><subject>Virus Diseases - therapy</subject><subject>Viruses</subject><issn>0146-6615</issn><issn>1096-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kctqGzEUhkVpaJy0i75AGeimgUxypNFtNoFicsWlm7RbIWs0tsyM5EozLt71EfKMeZKodRqSQlfnCH36ODo_Qu8xnGAAcrrqNyeE5_YVmmCoeVmDwK_RBDDlJeeY7aODlFYAIGtC3qD9ilBBBPAJmt0ubdEFv7j_dZcG7RvnF8XSpSHEbRHaYpqrt3NtBhvd2BdrHTdjf1y4vh-9G7bHRX5TbFwck01v0V6ru2TfPdZD9O3i_HZ6Vc6-Xl5PP89KUzEJpbQCGGa4krWBhlRZz2QtuGa2ZhWVlhutDa6oYIKbOdUkn2kDbSsNp9BUh-hs512P8942xvoh6k6to-t13KqgnXp5491SLcJGiQpAMJYFnx4FMfwYbRpU75KxXae9DWNShILEeVUYZ_TjP-gqjNHn72WK8lpyxnimjnaUiSGlaNunYTCo3xmpnJH6k1FmPzyf_on8G0oGTnfAT9fZ7f9N6ubL953yAZJtnMc</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Palmieri, Beniamino</creator><creator>Vadalà, Maria</creator><creator>Roncati, Luca</creator><creator>Garelli, Andrea</creator><creator>Scandone, Francesco</creator><creator>Bondi, Moreno</creator><creator>Cermelli, Claudio</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7873-5072</orcidid><orcidid>https://orcid.org/0000-0003-3396-0000</orcidid><orcidid>https://orcid.org/0000-0002-0871-138X</orcidid><orcidid>https://orcid.org/0000-0002-6652-9148</orcidid></search><sort><creationdate>202011</creationdate><title>The long‐standing history of Corynebacterium parvum, immunity, and viruses</title><author>Palmieri, Beniamino ; Vadalà, Maria ; Roncati, Luca ; Garelli, Andrea ; Scandone, Francesco ; Bondi, Moreno ; Cermelli, Claudio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3580-8e705151389c0d23eba58976a5e95348e6caac1347576cb4a2caa4d0ff8c640d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Antiviral activity</topic><topic>C. parvum</topic><topic>Clinical Trials as Topic</topic><topic>coronavirus</topic><topic>Corynebacterium</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>Humans</topic><topic>immune responses</topic><topic>Immunity</topic><topic>Immunity, Innate</topic><topic>Immunologic Factors - administration & dosage</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunologic Surveillance</topic><topic>immunomodulation</topic><topic>Immunosurveillance</topic><topic>Innate immunity</topic><topic>Lethality</topic><topic>Oncolysis</topic><topic>Pandemics</topic><topic>Propionibacterium acnes - immunology</topic><topic>Review</topic><topic>Reviews</topic><topic>Virology</topic><topic>Virus Diseases - immunology</topic><topic>Virus Diseases - prevention & control</topic><topic>Virus Diseases - therapy</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Palmieri, Beniamino</creatorcontrib><creatorcontrib>Vadalà, Maria</creatorcontrib><creatorcontrib>Roncati, Luca</creatorcontrib><creatorcontrib>Garelli, Andrea</creatorcontrib><creatorcontrib>Scandone, Francesco</creatorcontrib><creatorcontrib>Bondi, Moreno</creatorcontrib><creatorcontrib>Cermelli, Claudio</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of medical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Palmieri, Beniamino</au><au>Vadalà, Maria</au><au>Roncati, Luca</au><au>Garelli, Andrea</au><au>Scandone, Francesco</au><au>Bondi, Moreno</au><au>Cermelli, Claudio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The long‐standing history of Corynebacterium parvum, immunity, and viruses</atitle><jtitle>Journal of medical virology</jtitle><addtitle>J Med Virol</addtitle><date>2020-11</date><risdate>2020</risdate><volume>92</volume><issue>11</issue><spage>2429</spage><epage>2439</epage><pages>2429-2439</pages><issn>0146-6615</issn><eissn>1096-9071</eissn><abstract>We report a review of all the experimental and clinical studies performed in the last 60 years on the antiviral activity of inactivated Corynebacterium parvum (Cutibacterium acnes). This bacterium has been originally investigated and used for its oncolytic properties linked to immunomodulating activity, but the interest to successfully prevent and treat bacterial, fungal, and viral infections and lethality, uprising the innate immunity barriers produced many experimental models and very few clinical studies. The dramatic defenseless situation due to impending CoViD‐19 pandemic claims to exhume and highlight this aspecific strategy in preventive and therapeutic settings; as a matter of fact, no new or mutated virus can potentially escape to this strong innate immune surveillance strengthened by adequate C. parvum protocols.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32472706</pmid><doi>10.1002/jmv.26100</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-7873-5072</orcidid><orcidid>https://orcid.org/0000-0003-3396-0000</orcidid><orcidid>https://orcid.org/0000-0002-0871-138X</orcidid><orcidid>https://orcid.org/0000-0002-6652-9148</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0146-6615 |
| ispartof | Journal of medical virology, 2020-11, Vol.92 (11), p.2429-2439 |
| issn | 0146-6615 1096-9071 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7300755 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Animals Antiviral activity C. parvum Clinical Trials as Topic coronavirus Corynebacterium COVID-19 COVID-19 - prevention & control Humans immune responses Immunity Immunity, Innate Immunologic Factors - administration & dosage Immunologic Factors - therapeutic use Immunologic Surveillance immunomodulation Immunosurveillance Innate immunity Lethality Oncolysis Pandemics Propionibacterium acnes - immunology Review Reviews Virology Virus Diseases - immunology Virus Diseases - prevention & control Virus Diseases - therapy Viruses |
| title | The long‐standing history of Corynebacterium parvum, immunity, and viruses |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-23T18%3A03%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20long%E2%80%90standing%20history%20of%20Corynebacterium%20parvum,%20immunity,%20and%20viruses&rft.jtitle=Journal%20of%20medical%20virology&rft.au=Palmieri,%20Beniamino&rft.date=2020-11&rft.volume=92&rft.issue=11&rft.spage=2429&rft.epage=2439&rft.pages=2429-2439&rft.issn=0146-6615&rft.eissn=1096-9071&rft_id=info:doi/10.1002/jmv.26100&rft_dat=%3Cproquest_pubme%3E2408192211%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3580-8e705151389c0d23eba58976a5e95348e6caac1347576cb4a2caa4d0ff8c640d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2446986556&rft_id=info:pmid/32472706&rfr_iscdi=true |